Aligos Therapeutics Inc's mission is to become a world leader in the development of targeted therapies for liver diseases and viral infections, including NASH and COVID-19. The company's pipeline includes several drug candidates that target clinically validated mechanisms of action in NASH and viral diseases, such as ALG-010133, ALG-000184, ALG-020572, and ALG-055009. Aligos Therapeutics leverages its expertise in liver diseases to rapidly advance its pipeline of potentially best-in-class molecules.